Edwards Lifesciences Corporation (EW) 当前追踪市盈率 (P/E) 为 43.6, 前瞻市盈率为 26.3. 追踪盈利收益率为 2.30%, 前瞻盈利收益率 3.80%. PEG 0.42 (Peter Lynch 低估标准 ≤1.0). 格雷厄姆数为 $27.18.
本页证实的标准:
SharesGrow 综合评分： 74/100 其中 6/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | 35.0 | 2.25 | 7.62 | 6.73 | - |
| 2017 | 38.2 | 3.78 | 7.94 | 6.92 | - |
| 2018 | 44.4 | 2.56 | 10.20 | 8.61 | - |
| 2019 | 46.4 | 1.01 | 11.71 | 11.18 | - |
| 2020 | 69.0 | -3.22 | 12.42 | 12.95 | - |
| 2021 | 53.7 | 0.65 | 13.84 | 15.43 | - |
| 2022 | 30.3 | 14.63 | 7.95 | 8.58 | - |
| 2023 | 33.0 | -5.41 | 6.96 | 9.23 | - |
| 2024 | 10.6 | 0.05 | 4.43 | 8.13 | - |
| 2025 | 46.4 | -0.63 | 4.82 | 8.22 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $0.87 | $2.96B | $569.5M | 19.2% |
| 2017 | $0.96 | $3.44B | $622.1M | 18.1% |
| 2018 | $1.13 | $3.72B | $722.2M | 19.4% |
| 2019 | $1.64 | $4.35B | $1.05B | 24.1% |
| 2020 | $1.30 | $4.39B | $823.4M | 18.8% |
| 2021 | $2.38 | $5.23B | $1.5B | 28.7% |
| 2022 | $2.44 | $5.38B | $1.52B | 28.3% |
| 2023 | $2.30 | $6B | $1.4B | 23.4% |
| 2024 | $6.97 | $5.44B | $4.17B | 76.7% |
| 2025 | $1.83 | $6.07B | $1.07B | 17.7% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $2.97 | $2.83 – $3.02 | $6.68B | $6.63B – $6.72B | 16 |
| 2027 | $3.32 | $3.17 – $3.42 | $7.34B | $7.27B – $7.41B | 16 |
| 2028 | $3.73 | $3.54 – $3.92 | $8.07B | $8.06B – $8.07B | 4 |
| 2029 | $4.20 | $4.13 – $4.27 | $8.89B | $8.76B – $9B | 2 |
| 2030 | $4.56 | $4.48 – $4.64 | $9.68B | $9.55B – $9.81B | 2 |
